
About Partner Therapeutics
Partner Therapeutics is a Healthcare company based in Lexington (United States) founded in 2017. Partner Therapeutics is focused on developing and commercializing therapeutics for cancer and serious diseases. It operates on a HealthTech and Direct-to-Consumer (D2C) model. Partner Therapeutics has raised $60 million across 1 funding round from investors including MidCap Financial, Perceptive Advisors and Adams Street Partners. The company has 168 employees. Partner Therapeutics has completed 1 acquisition, including LEUKINE. Partner Therapeutics offers products and services including IMREPLYS® (sargramostim, rhu GM-CSF), Zenocutuzumab-zbco (BIZENGRI®), and LEUKINE. Its focus areas include Biotechnology and Cancer Therapeutics. Its legal entity is Partner Therapeutics, Inc. Its competitors include Revolution Medicines, Blueprint Medicines and Syndax; 3 of its 3 listed competitors have raised funding.
Company details
Partner Therapeutics, an integrated biotechnology company, is engaged in the development and commercialization of late-stage therapeutics aimed at improving health outcomes for cancer and other serious diseases. The company is also involved in creating host-directed therapeutic treatments for global health security threats. Their work spans across supporting medical teams and delivering products with a focus on achieving superior patient outcomes. Research and clinical trials are conducted to evaluate and advance their therapeutic solutions like IMREPLYS for radiation exposure and Zenocutuzumab for NRG1 cancer.
- Headquarters Lexington, United States
- Employees 168
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website partnertx.com
- Social LinkedIn X Facebook
- Legal Name Partner Therapeutics, Inc.
- Total Equity Funding$60M (USD)
in 1 rounds
- Latest Funding Round$60M (USD), Series A
Feb 2018
- InvestorsMidCap Financial
& 2 more
- Employee Count168
- Investments & Acquisitions
Products & Services of Partner Therapeutics
Partner Therapeutics offers a comprehensive portfolio of products and services, including IMREPLYS® (sargramostim, rhu GM-CSF), Zenocutuzumab-zbco (BIZENGRI®), and LEUKINE.
Used for treating radiation exposure in hematology cases.
Developed for treating NRG1+ cancer in patients.
Licensed therapeutic for serious disease treatment support.
Funding Insights of Partner Therapeutics
Partner Therapeutics has successfully raised a total of $60M through 1 strategic funding round. The most recent funding activity was a Series A round of $60 million completed in February 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $60M
- Total Rounds 1
- Last Round Series A — $60M
- First Round $60M
(Feb 2018)
- Investors Count 3
All 1 funding rounds of Partner Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2018 | $60M | Series A | – | Perceptive Advisors |
3 investors in total: 3 institutional.
Investors in Partner Therapeutics
Partner Therapeutics has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include MidCap Financial, Perceptive Advisors and Adams Street Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Private markets investment management with strategies in equity, credit, and secondary investments. | adamsstreetpartners.com | |||
Private debt funds are managed across multiple sectors. | 2008 | midcapfinancial.com | Bethesda, United States |
Investor details for Partner Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Partner Therapeutics
59 people are tracked at Partner Therapeutics (30 in leadership, 29 in team); the tracked headcount is 168.
| Name | Role | Group |
|---|---|---|
Bronte Abraham | Senior Director, Operations (compliance, Commercial, Medical And Strategy) | Leadership |
Robert Mulroy | CEO | Leadership |
Sarah Kurz | President And Chief Operating Officer | Leadership |
Bill McClements | Chief Financial & Operations Officer | Leadership |
James Picardi | Director, Market Access (payer, Gpo, Specialty Pharmacy) - Oncology | Leadership |
Danielle Pettigrew, MS | Director, Market Access (gpo, Reimbursement, Value, Patient Services) | Leadership |
Jay Harding, PACS | Sr. Director, Market Access & National Accounts | Leadership |
Scott Armondino | Senior Director, Business Technology and Operations | Leadership |
Sandy D. | Vice President, Commercial Operations | Leadership |
Melanie Dyjak, M.S. | Associate Director, Clinical Operations | Leadership |
Sanjeev Ahuja, MD, MBA, FACP | Chief Development Officer: Neurology, Critical Care and Health Security | Leadership |
Jeff Minor | Director, Corporate Accounts - Oncology | Leadership |
Matt Nestor | Vice President, New Product Planning and Product Team Leader | Leadership |
Steven McAdams | Associate Director: Health, Safety, Security, Environment | Leadership |
Jeff Gardin | Associate Director, Technology | Leadership |
John McManus | Chief Business Officer | Leadership |
Debasish Roychowdhury | CTO | Leadership |
Emil Cakiryan | Associate Director, Financial Operations And Fp&a | Leadership |
Pat Thompson | National Accounts Director | Leadership |
John Mulroy | Senior Vice President Finance, Treasurer | Leadership |
39 more people are available in the full profile.
Complete people profiles for Partner Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Partner Therapeutics
Partner Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include LEUKINE.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Information on infection drugs is provided via the Leukine website. | leukine.com | Boston, United States | 1998 | Jan 2018 | •••• |
Complete acquisition details for Partner Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Partner Therapeutics
3 dated milestones of Partner Therapeutics across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Partner Therapeutics is founded.
- Acquisition Acquires LEUKINE.
- Funding First funding round of $60.0M.
Competitors of Partner Therapeutics
Partner Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Revolution Medicines, Blueprint Medicines and Syndax.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. |
Detailed competitors of Partner Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Partner Therapeutics
The website of Partner Therapeutics (partnertx.com) receives about 5.6K visits a month.
- Monthly visits5.6K
▲ 31.6% vs previous month
Top companies in Oncology
3 companies that operate in the same segment as Partner Therapeutics (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Partner Therapeutics
Complete news archive for Partner Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Partner Therapeutics
Partner Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Partner Therapeutics is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Partner Therapeutics is a funded company, having raised a total of $60M across 1 funding round to date. The company's 1st funding round was a Series A of $60M, raised on Feb 2018.
Partner Therapeutics has 168 employees.
Partner Therapeutics, an integrated biotechnology company, is engaged in the development and commercialization of late-stage therapeutics aimed at improving health outcomes for cancer and other serious diseases. The company is also involved in creating host-directed therapeutic treatments for global health security threats. Their work spans across supporting medical teams and delivering products with a focus on achieving superior patient outcomes. Research and clinical trials are conducted to evaluate and advance their therapeutic solutions like IMREPLYS for radiation exposure and Zenocutuzumab for NRG1 cancer.
Partner Therapeutics's top competitors include Syndax, Revolution Medicines and Blueprint Medicines.
Partner Therapeutics offers IMREPLYS® (sargramostim, rhu GM-CSF), Zenocutuzumab-zbco (BIZENGRI®), and LEUKINE.
Partner Therapeutics has made 1 acquisition, including LEUKINE.
Partner Therapeutics has 3 investors. Key investors include MidCap Financial, Perceptive Advisors, and Adams Street Partners.
Partner Therapeutics operates through Partner Therapeutics, Inc..
